AGS 009

Drug Profile

AGS 009

Alternative Names: AGS-009; NNC 0152-0000-0001

Latest Information Update: 18 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Argos Therapeutics Inc
  • Class Monoclonal antibodies
  • Mechanism of Action Interferon alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Systemic lupus erythematosus

Most Recent Events

  • 31 Dec 2013 Phase-I clinical trials in Systemic lupus erythematosus have been completed in USA (IV)
  • 07 Jun 2012 Adverse events, pharmacodynamics, and pharmacokinetics data from a phase Ia trial in Systemic lupus erythematosus presented at the 13th Annual Congress of the European League Against Rheumatism (EULAR-2012)
  • 01 Dec 2011 Argos Therapeutics completes a phase I trial in Systemic lupus erythematosus in USA (NCT00960362)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top